Dr. Saad Z. Usmani | CureTalks
Dr. Saad Z. Usmani MD, is a clinical associate professor of medicine at the UNC-Chapel Hill School of Medicine, director of the plasma cell disorder program at Levine Cancer Institute, as well as the director of clinical research in hematologic malignancies at the Levine Cancer Institute/Carolinas Healthcare System. Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut.Dr. Usmani is a member of the International Myeloma Working Group, the SWOG Myeloma Committee, the American Society of Hematology, the American Society of Clinical Oncology, and the American Society of Bone Marrow Transplantation. He also serves on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, the ASH Committee on Plasma Cell Neoplasia, and the NCI Myeloma Steering Committee. Dr. Usmani is on the editorial review board of numerous medical journals, has authored/co-authored more than 70 peer-reviewed research manuscripts and 90 abstracts at national and international meetings. He has also served as the PI/co-PI for over 35 clinical trials (Phase I-III). A specialist in hematology, medical oncology and bone marrow transplantation, Dr. Usmani’s clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma.
Related Talks
Immunotherapy Advances in Multiple Myeloma
Recent years have seen the emergence of immunotherapy as a leading form of treatment for multiple myeloma. New strategies such as monoclonal antibody…
The New Optimism of Combination Therapies in Multiple Myeloma Treatment.
Clinical trials of new combination therapies are showing promising results and can be a game changer in myeloma treatment - Combining standard drugs…